Licensing Partnerships CALYPSO Biotech has CALY-001 anti-MMP-9 antibody and a collaboration with EA Pharma, signaling openness to licensing and co-development deals for autoimmune indications. Target regional biotech and mid-sized pharma players in Europe, US, and Asia seeking novel autoimmune therapies; propose initial outreach to licensing teams and a concise value proposition: diverse development paths, risk sharing, and access to innovative antibody platforms.

Outsourcing Ready As a small company with limited internal development capacity, CALYPSO is well positioned to engage CMOs and CROs for preclinical and early clinical work, scale-up manufacturing, and regulatory support. Offer end-to-end development packages, including antibody discovery-to-clinical supply chain, with flexible milestones to align with their funding timelines.

Investor Credibility Backed by notable life sciences investors and a growing board, CALYPSO can attract co-investors and strategic partners to fund expansion of the CALY-001 program. Use investor familiarity to position co-development or milestone-based financing options to potential partners and grant programs.

Global Access With a Netherlands base and international partnerships, CALYPSO is well-placed to pursue European, US, and Asian market access via licensing, distribution deals, or manufacturing partnerships. Highlight regulatory familiarity in Europe and potential for cross-border trials; explore opportunities with EU funding or grant programs and Asia-focused distributors.

Clinical Momentum Recent leadership enhancements signal a deliberate push toward clinical development, enhancing credibility with potential partners and CROs. Use this to present a clear clinical roadmap and potential urgency for collaboration on trial design, biomarker strategies around MMP-9, and regulatory strategy.